Author

N. Yamamoto

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

E7386 plus lenvatinib in patients with advanced endometrial cancer that progressed on platinum-based chemotherapy and an anti-PD-(L)1 immunotherapy: a single-arm, open-label, global phase 1b/2 dose-expansion cohort

Summary Background Novel therapies are needed for advanced endometrial cancer (aEC) that recurs after chemotherapy + immunotherapy. Lenvatinib has antitumour activity in patients with aEC after platinum-based chemotherapy and is approved in combination with pembrolizumab for aEC following prior systemic therapy. E7386,...

Jung-Yun Lee, K. Hasegawa, Byoung-Gie Kim et al. · EClinicalMedicine · 0 citations

Open access Aug 2026

A Phase 1 First-Time-in-Human, Open-Label Study of Nelistotug Administered to Patients with Advanced Solid Tumors.

PURPOSE This first-in-human, nonrandomized, multicenter study investigated nelistotug (anti-CD96 monoclonal antibody [mAb]) as monotherapy (Arm A) and in combination with dostarlimab (anti-PD-1 mAb) (Arm B), and dostarlimab plus belrestotug (anti-TIGIT mAb) (Arm F) in patients with recurrent or advanced solid tumors....

L. Siu, Omid Hamid, Reva Schneider et al. · Clinical Cancer Research · 0 citations

Open access Sep 2026

16 ABBV-CLS-484: A Novel Oral PTPN2/1 Inhibitor for Cancer Immunotherapy

Abstract Background ABBV-CLS-484 is a first-in-class oral PTPN2/N1 inhibitor with a dual mechanism of action that both increases the immunogenicity of tumor cells and augments the antitumor T cell response. It has monotherapy efficacy in multiple preclinical tumor models, with comparable activity to anti-PD-1 in many c...

H. Hammers, E. Calvo, B. Carneiro et al. · The Oncologist · 0 citations